Kristen Sweet

653 total citations
21 papers, 472 citations indexed

About

Kristen Sweet is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, Kristen Sweet has authored 21 papers receiving a total of 472 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Rheumatology, 12 papers in Immunology and 6 papers in Hematology. Recurrent topics in Kristen Sweet's work include Psoriasis: Treatment and Pathogenesis (11 papers), Spondyloarthritis Studies and Treatments (10 papers) and Rheumatoid Arthritis Research and Therapies (8 papers). Kristen Sweet is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (11 papers), Spondyloarthritis Studies and Treatments (10 papers) and Rheumatoid Arthritis Research and Therapies (8 papers). Kristen Sweet collaborates with scholars based in United States, United Kingdom and Germany. Kristen Sweet's co-authors include Kim Campbell, Elizabeth C. Hsia, Atul Deodhar, Désirée van der Heijde, Lianne S. Gensler, Michael B. Clark, Diane D. Harrison, Joachim Sieper, Jocelyn H. Leu and Yiying Zhou and has published in prestigious journals such as Blood, Annals of the Rheumatic Diseases and Arthritis & Rheumatology.

In The Last Decade

Kristen Sweet

19 papers receiving 460 citations

Peers

Countries citing papers authored by Kristen Sweet

Since Specialization

Citations

This map shows the geographic impact of Kristen Sweet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kristen Sweet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kristen Sweet more than expected).

Fields of papers citing papers by Kristen Sweet

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kristen Sweet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kristen Sweet. The network helps show where Kristen Sweet may publish in the future.

Co-authorship network of co-authors of Kristen Sweet

This figure shows the co-authorship network connecting the top 25 collaborators of Kristen Sweet. A scholar is included among the top collaborators of Kristen Sweet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kristen Sweet. Kristen Sweet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Guselkumab Modulates Differentially Expressed Genes in Blood of Patients With Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo‐Controlled Trials 2023 ·ACR Open Rheumatology ·Stefan Siebert, Kristen Sweet, Christopher T. Ritchlin, Elizabeth C. Hsia, Alexa P. Kollmeier, Xie L. Xu, Loqmane Seridi, Qingxuan Song, Sheng Gao, (unknown), Michelle Miron	2
2	Genetic and Molecular Distinctions Between Axial Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: Post Hoc Analyses from Four Phase 3 Clinical Trials 2023 ·Advances in Therapy ·Arthur Kavanaugh, Xenofon Baraliakos, Sheng Gao, (unknown), Kristen Sweet, Soumya D. Chakravarty, Qingxuan Song, M. Shawi, Proton Rahman	11
3	Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2) 2022 ·Rheumatology and Therapy ·Georg Schett, Matthew J. Loza, Arumugam Palanichamy, Oliver FitzGerald, Christopher T. Ritchlin, Anne‐Christine Bay‐Jensen, Signe Holm Nielsen, Sheng Gao, Elizabeth C. Hsia, Alexa P. Kollmeier, Xie L. Xu, Frédéric Baribaud, Kristen Sweet	15
4	Energy Trial in Warm Autoimmune Hemolytic Anemia (wAIHA): Design of a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nipocalimab, an FcRn Blocker 2022 ·Blood ·(unknown), Bruno Fattizzo, (unknown), Kristen Sweet, (unknown)	3
5	Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials 2021 ·RMD Open ·Kristen Sweet, Qingxuan Song, Matthew J. Loza, Iain B. McInnes, Keying Ma, Karen Leander, Vani Lakshminarayanan, (unknown), Philip Cooper, Stefan Siebert	32
6	Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies 2021 ·The Lancet Rheumatology ·Philip J. Mease, Philip Helliwell, Dafna D. Gladman, Denis Poddubnyy, Xenofon Baraliakos, Soumya D. Chakravarty, Alexa P. Kollmeier, Elizabeth C. Hsia, Xie L. Xu, Shihong Sheng, Prasheen Agarwal, Bei Zhou, Kristen Sweet, M. Shawi, Chetan S. Karyekar, Atul Deodhar, Désirée van der Heijde	61
7	POS0195 GUSELKUMAB TREATMENT MODULATES CORE PSORIATIC ARTHRITIS GENE EXPRESSION IN TWO PHASE 3 CLINICAL TRIALS (DISCOVER-1 AND -2) 2021 ·Annals of the Rheumatic Diseases ·Stefan Siebert, Kristen Sweet, Christopher T. Ritchlin, Elizabeth C. Hsia, Alexa P. Kollmeier, X. L. Xu, Qingxuan Song, (unknown)	4
8	Gluten-induced Neurocognitive Impairment 2021 ·Journal of Clinical Gastroenterology ·Jessica B. Edwards George, (unknown), Kayla Yates, (unknown), (unknown), Kristen Sweet, (unknown), (unknown), (unknown), Daniel A. Leffler	11
9	POS1036 COLLAGEN TURNOVER MARKERS ARE ASSOCIATED WITH ACTIVE PSORIATIC ARTHRITIS AND DECREASE WITH GUSELKUMAB TREATMENT IN A PHASE-3 CLINICAL TRIAL 2021 ·Annals of the Rheumatic Diseases ·Georg Schett, (unknown), Arumugam Palanichamy, Oliver FitzGerald, Christopher T. Ritchlin, Frédéric Baribaud, Kristen Sweet	1
10	EFFICACY OF GUSELKUMAB, A MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THE P19 SUBUNIT OF IL-23, ON AXIAL-RELATED ENDPOINTS IN PATIENTS WITH ACTIVE PSA WITH IMAGING-CONFIRMED SACROILIITIS: WEEK-52 RESULTS FROM TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES 2021 ·(unknown), Philip Mease, Philip Helliwell, Dafna D. Gladman, Denis Poddubnyy, Désirée van der Heijde, Kristen Sweet, Atul Deodhar, Chetan S. Karyekar, M. Shawi, Bei Zhou, Prasheen Agarwal, Shihong Sheng, Xenofon Baraliakos, Soumya D. Chakravarty, Alexa P. Kollmeier, Elizabeth C. Hsia, (unknown)	2
11	OP0229 GUSELKUMAB INDUCES SUSTAINED REDUCTION IN ACUTE PHASE PROTEINS AND TH17 EFFECTOR CYTOKINES IN ACTIVE PSORIATIC ARTHRITIS IN TWO PHASE-3 CLINICAL TRIALS (DISCOVER-1 AND DISCOVER-2) 2020 ·Annals of the Rheumatic Diseases ·Stefan Siebert, Iain B. McInnes, Matthew J. Loza, Ketao Ma, Karen Leander, Vani Lakshminarayanan, (unknown), Philip Cooper, Kristen Sweet	1
12	Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials 2020 ·RMD Open ·Philip Helliwell, Dafna D. Gladman, Soumya D. Chakravarty, Shelly Kafka, Chetan S. Karyekar, Yin You, Kim Campbell, Kristen Sweet, Arthur Kavanaugh, Lianne S. Gensler	39
13	OP0161 ASSOCIATION OF BASELINE CYTOTOXIC GENE EXPRESSION WITH USTEKINUMAB RESPONSE IN SYSTEMIC LUPUS ERYTHEMATOSUS 2020 ·Annals of the Rheumatic Diseases ·Loqmane Seridi, Matteo Cesaroni, Matthew J. Loza, Jessica Schreiter, Kristen Sweet, (unknown), (unknown), Ashley Orillion, Peter E. Lipsky, Ronald van Vollenhoven, Beatrice H. Hahn, George C. Tsokos, Marc Chévrier, Shawn Rose, Frédéric Baribaud, Jarrat Jordan	2
14	Suppression of Serum Interferon‐γ Levels as a Potential Measure of Response to Ustekinumab Treatment in Patients With Systemic Lupus Erythematosus 2020 ·Arthritis & Rheumatology ·Matteo Cesaroni, Loqmane Seridi, Matthew J. Loza, Jessica Schreiter, Kristen Sweet, (unknown), (unknown), Ashley Orillion, Kim Campbell, Robert Gordon, Patrick Branigan, Peter E. Lipsky, Ronald van Vollenhoven, Bevra H. Hahn, George C. Tsokos, Marc Chévrier, Shawn Rose, Frédéric Baribaud, Jarrat Jordan	22
15	Responsiveness of Serum C‐Reactive Protein, Interleukin‐17A, and Interleukin‐17F Levels to Ustekinumab in Psoriatic Arthritis: Lessons From Two Phase III, Multicenter, Double‐Blind, Placebo‐Controlled Trials 2019 ·Arthritis & Rheumatology ·Stefan Siebert, Kristen Sweet, B. Dasgupta, Kim Campbell, Iain B. McInnes, Matthew J. Loza	15
16	OP0278 BIOMARKER PROFILING REVEALS NOVEL MECHANISTIC INSIGHTS INTO USTEKINUMAB THERAPEUTIC RESPONSES IN SYSTEMIC LUPUS ERYTHEMATOSUS 2019 ·Annals of the Rheumatic Diseases ·Matteo Cesaroni, Loqmane Seridi, Jarrat Jordan, Kristen Sweet, (unknown), (unknown), Jessica Schreiter, Peter E. Lipsky, Ronald van Vollenhoven, Bevra H. Hahn, Shawn Rose, (unknown), Matthew J. Loza, Kim Campbell, George C. Tsokos	1
17	251 Type II but not type I interferon signifies clinical response to ustekinumab in patients with systemic lupus erythematosus 2019 ·Abstracts ·Jarrat Jordan, Kristen Sweet, Matteo Cesaroni, Keying Ma, (unknown), Loqmane Seridi, Jessica Schreiter, Robert Gordon, Peter E. Lipsky, Ronald van Vollenhoven, George C. Tsokos, Bevra H. Hahn, Shawn Rose, (unknown), Matthew J. Loza, Kim Campbell	0
18	THU0052 USTEKINUMAB AND GUSELKUMAB TREATMENT RESULTS IN DIFFERENCES IN SERUM IL17A, IL17F AND CRP LEVELS IN PSORIATIC ARTHRITIS PATIENTS: A COMPARISON FROM USTEKINUMAB PH3 AND GUSELKUMAB PH2 PROGRAMS 2019 ·Annals of the Rheumatic Diseases ·Stefan Siebert, Matthew J. Loza, Qingxuan Song, Iain B. McInnes, Kristen Sweet	10
19	Three Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis 2018 ·Arthritis & Rheumatology ·Atul Deodhar, Lianne S. Gensler, Joachim Sieper, Michael B. Clark, César A. Calderón, Yuhua Wang, Yiying Zhou, Jocelyn H. Leu, Kim Campbell, Kristen Sweet, Diane D. Harrison, Elizabeth C. Hsia, Désirée van der Heijde	238
20	OP0103 The effect of sirukumab plus methotrexate on circulating biomarkers of joint destruction in moderate to severe rheumatoid arthritis patients from the sirround-d phase 3 study 2017 ·Annals of the Rheumatic Diseases ·B. Dasgupta, Kim Campbell, Anne‐Christine Bay‐Jensen, M.A. Karsdal, Kristen Sweet, (unknown), (unknown)	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact